Outcome research: Ambulatory intraperitoneal chemotherapy in stage IIIC ovarian cancer
| العنوان: | Outcome research: Ambulatory intraperitoneal chemotherapy in stage IIIC ovarian cancer |
|---|---|
| المؤلفون: | Nelson Kohen, Sebastian Alessandria, Claudio Levit, Eduardo L. Morgenfeld, Edgardo G. J. Rivarola, Felipe G. Gercovich, Ernesto Gil Deza, Carlos Fernando Garcia Gerardi, Javier Vidaurreta |
| المصدر: | Journal of Clinical Oncology. 30:e15507-e15507 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Stage III Ovarian Cancer, Oncology, Cancer Research, medicine.medical_specialty, Stage IIIC Ovarian Cancer, business.industry, Internal medicine, Ambulatory, Medicine, Intraperitoneal chemotherapy, business |
| الوصف: | e15507 Background: Intraperitoneal chemotherapy in stage III ovarian cancer is indicated following the results of the GOG 172 study but the ambulatory application of the scheme in 24 hours continuous infusion is not feasible. Following expert recommendations (Walker, ASCO 2009 Educational Book), we evaluated the feasibility of administrating a modified GOG 172 regime in an ambulatory form. Methods: Between September 2009 and October 2010, ten patients diagnosed with stage IIIC ovarian cancer and optimal cytoreduction received the following treatment in ambulatory form: IV paclitaxel (135mg/m2/3hrs Day 1), followed by IP cisplatin (60-75mg/m2 Day 2), plus IP paclitaxel (60mg/m2 Day 8). Cycles were administered every 21 days, up to a maximum of six cycles. The tolerance for this treatment was evaluated according to the CTC for Adverse Event 3.0. Results: Population Characteristics: Mean age (47 years; range 26-64). PS (0: 4 pt; 1: 6 pt). Pathology (Papillary: 7 Pts; Mucinous, Endometroid and Poorly Differentiated: 1 pt each). N-positives: 4 pt; N-negatives: 6 pt. Intestinal resection: 1pt. In all cases, treatment was applied according to the specified parameters. Total number of cycles administered: 37 (mean cycles per pt 3 range 2-6). The average time of treatment application was 3 hours per day (9 hours total). Toxicity (G3-4): Leukopenia (2 pts). Toxicity (G1-2): Alopecia (10 pts), Anemia (9 pts), Myalgia (8 pts), Neurologic (7 pts), Fatigue (6 pts), Nausea and vomiting (6pt), Renal (2 pts), Allergy (1 pt), Pain at Catheter site (1 pt). With an average follow up time of 16 months (Range: 9-26), none of the patients have died. Three patients have progressed after the Intraperitoneal chemotherapy, while seven are alive without evidence of disease after the treatment. Conclusions: 1) The modified GOG 172 scheme can be safely applied in an ambulatory form. 2) The time required for applying the treatment is similar to that of other frequently used treatments (BEP, paclitaxel – trastuzumab, R-CHOP, b-FOL). 3) Patient tolerance was very good. 4) With an average follow-up of 16 months, all 10 patients are alive and 7 of them remain free of disease. |
| تدمد: | 1527-7755 0732-183X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::ad57d61581f876cf73e979da1cb8ce6e https://doi.org/10.1200/jco.2012.30.15_suppl.e15507 |
| رقم الأكسشن: | edsair.doi...........ad57d61581f876cf73e979da1cb8ce6e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|